StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Axsome Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -24.0%. For fiscal 2025 it was -26.1%, against -72.7% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-26.1%+46.6
FY2024Dec 31, 2024-72.7%+12.9
FY2023Dec 31, 2023-85.7%+273.7
FY2022Dec 31, 2022-359.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-22.7%+1.7
Q1 FY2026Mar 31, 2026-33.1%+13.8
Q4 FY2025Dec 31, 2025-13.8%+47.4
Q3 FY2025Sep 30, 2025-27.0%+32.8
Q2 FY2025Jun 30, 2025-24.5%+65.1
Q1 FY2025Mar 31, 2025-46.9%+42.8
Q4 FY2024Dec 31, 2024-61.1%+76.2
Q3 FY2024Sep 30, 2024-59.8%+47.7
Q2 FY2024Jun 30, 2024-89.5%+49.8
Q1 FY2024Mar 31, 2024-89.7%−83.0
Q4 FY2023Dec 31, 2023-137.4%+108.5
Q3 FY2023Sep 30, 2023-107.5%+144.3
Q2 FY2023Jun 30, 2023-139.3%+304.9
Q1 FY2023Mar 31, 2023-6.7%–
Q4 FY2022Dec 31, 2022-245.9%–
Q3 FY2022Sep 30, 2022-251.8%–
Q2 FY2022Jun 30, 2022-444.2%–

More Axsome Therapeutics figures

See a number that looks wrong?